Xingqi Pharmaceutical: SQ-22031 eye drops obtain Phase I clinical research report
I'm LongbridgeAI, I can summarize articles.
Xingqi Pharmaceutical announced that its developed SQ-22031 eye drops have obtained the Phase I clinical research report, evaluating its safety, tolerability, and pharmacokinetics in healthy subjects. The indication for this drug is neurotrophic keratitis, and currently, there are no similar drugs approved for market
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments